Northwire Canada EditionSaturday, October 17, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4181.10 +0.3% SILVER 57.30 +0.3% COPPER 6.57 +0.3% OIL 99.02 +1.1% PALLADIUM 1118.60 −0.9% GBU 0.095 +0.0% ATY 0.225 +4.7% GRDM 0.215 +0.0% PPM 0.300 +0.0% GZD 0.040 −11.1% CAN 0.060 +0.0% BGF 0.025 +0.0% MSV 0.570 +0.0% CCMM 0.485 +0.0% MON 0.385 −6.1% OMI 0.245 −2.0% BUFF 0.800 +2.6% FEO 0.630 −3.1% LIB 0.710 −1.4% NPR 0.620 +0.0% QZM 0.380 +0.0% GOLD 4181.10 +0.3% SILVER 57.30 +0.3% COPPER 6.57 +0.3% OIL 99.02 +1.1% PALLADIUM 1118.60 −0.9% GBU 0.095 +0.0% ATY 0.225 +4.7% GRDM 0.215 +0.0% PPM 0.300 +0.0% GZD 0.040 −11.1% CAN 0.060 +0.0% BGF 0.025 +0.0% MSV 0.570 +0.0% CCMM 0.485 +0.0% MON 0.385 −6.1% OMI 0.245 −2.0% BUFF 0.800 +2.6% FEO 0.630 −3.1% LIB 0.710 −1.4% NPR 0.620 +0.0% QZM 0.380 +0.0%

Healthcare

Page 75
  1. Jan 13, 2026 · 09:05 · CNVI

    Conavi Medical Corp. Announces Closing of $12M Public Offering

    Conavi Medical Corp. Announces Closing of $12M Public Offering

    01
  2. Jan 13, 2026 · 09:01 · TTI

    Thiogenesis Therapeutics' MELAS Abstract Accepted for Late-Breaking News Presentation at Mitocon 2026

    Thiogenesis Therapeutics' MELAS Abstract Accepted for Late-Breaking News Presentation at Mitocon 2026

    02
  3. Jan 13, 2026 · 09:00 · ADK

    DIAGNOS Advances Regulatory Strategy for CARA in Key Markets: Updates on Health Canada, FDA, and SFDA Progress

    DIAGNOS Advances Regulatory Strategy for CARA in Key Markets: Updates on Health Canada, FDA, and SFDA Progress

    03
  4. Jan 13, 2026 · 07:30 · BCT

    BriaCell Reports Sustained Complete Resolution of Lung Metastasis in Bria-OTS(TM) Patient

    BriaCell Reports Sustained Complete Resolution of Lung Metastasis in Bria-OTS(TM) Patient

    04
  5. Jan 13, 2026 · 07:30 · GLAS

    University of California Berkeley and Glass House Collaboration Leads to State-Funded Research on Cannabis Crop Yields

    University of California Berkeley and Glass House Collaboration Leads to State-Funded Research on Cannabis Crop Yields

    05
  6. Jan 13, 2026 · 07:28 · CRDL

    Cardiol Therapeutics Achieves Key 50% Patient Enrollment Milestone in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis

    Cardiol Therapeutics Achieves Key 50% Patient Enrollment Milestone in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis

    06
  7. Jan 13, 2026 · 03:09 · 4565

    Nxera Pharma to Receive US$3.6 Million in Milestone Payment Pursuant to Research Collaboration with Centessa

    Nxera Pharma to Receive US$3.6 Million in Milestone Payment Pursuant to Research Collaboration with Centessa

    07
  8. Jan 12, 2026 · 18:44 · PRN

    Profound's Dec. 31 Tulsa-Pro installed base at 78

    Profound's Dec. 31 Tulsa-Pro installed base at 78

    08
  9. Jan 12, 2026 · 17:35 · TLT

    Theralase, Ferring sign clinical development agreement

    Theralase, Ferring sign clinical development agreement

    09
  10. Jan 12, 2026 · 17:31 · VIVI

    TempraMed Closes C$2.5 Million Fully Subscribed Private Placement

    TempraMed Closes C$2.5 Million Fully Subscribed Private Placement

    10
  11. Jan 12, 2026 · 08:52 · ZYUS

    ZYUS Life Sciences Announces LIFE Offering of a minimum of C$15 Million and maximum of C$16 Million of Units

    ZYUS Life Sciences Announces LIFE Offering of a minimum of C$15 Million and maximum of C$16 Million of Units

    11
  12. Jan 12, 2026 · 08:00 · PRN

    Profound Surpasses 2025 TULSA-PRO(TM) Installed Base Goal

    Profound Surpasses 2025 TULSA-PRO(TM) Installed Base Goal

    12
  13. Jan 12, 2026 · 07:01 · TLT

    Ferring Pharmaceuticals and Theralase(R) Technologies Announce Clinical Development Agreement to Investigate Combination Therapy in Bladder Cancer

    Ferring Pharmaceuticals and Theralase(R) Technologies Announce Clinical Development Agreement to Investigate Combination Therapy in Bladder Cancer

    13
  14. Jan 09, 2026 · 18:00 · DRUG

    Bright Minds closes $175-million (U.S.) public offering

    Bright Minds closes $175-million (U.S.) public offering

    14
← Newer Older →